SCHEMBL315186

SCHEMBL315186

Clc1ccc(C2CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.58
DRD2 P14416 1/20 0.55
SLC2A1 P11166 1/20 0.50
SLC18A3 Q16572 1/20 0.50
LMNA P02545 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 2/20 0.49
USP2 O75604 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
HIF1A Q16665 1/20 0.49
LSS P48449 1/20 0.47
CYP2A6 P11509 1/20 0.47
SRD5A1 P18405 2/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL15391253 0.92 DRD2 (0.55) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL18533598 0.92 HTR3A (0.52) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL23578560 0.90 HTR3A (0.50) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL19950989 0.90 MEN1 (0.59) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL218475 0.89 HTR3A (0.59) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL435619 0.89 HTR3A (0.59) HTR3ADRD2SLC2A1SLC18A3LMNA
Bicarbonate SCHEMBL1719769 0.88 IDO1 (0.51) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL8594378 0.88 HTR3A (0.48) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL8594377 0.88 HTR3A (0.48) HTR3ADRD2SLC2A1SLC18A3LMNA
SCHEMBL1570625 0.88 KDM1A (0.49) HTR3ADRD2SLC2A1SLC18A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572098-A Concrete additive and preparation method thereof 光明铁道控股有限公司 2023-01-06 CN claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
EP-2794573-B1 NOVEL INSECTICIDAL AROMATIC AMIDES BAYER IP GMBH (DE) 2017-08-30 EP claimed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 US claimed
US-9573966-B2 Anti-cancer activity of novel bicyclic heterocycles KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2017-02-21 US claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 EP claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US claimed
EP-2616077-B1 ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES UNIV LEUVEN KATH (BE) 2016-08-31 EP claimed
EP-2782903-B1 NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN HOFFMANN LA ROCHE (CH) 2016-04-06 EP claimed
US-9204645-B2 Insecticidal aromatic amides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-08 US claimed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US claimed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO claimed
EP-1756063-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-02-28 EP claimed
WO-2005110992-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2005-11-24 WO claimed
US-5051447-A Applying aromatic oximes to plants, seeds or soils BASF AKTIENGESELLSCHAFT (DE) 1991-09-24 US claimed
EP-0179788-B1 PESTICIDES NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1991-06-12 EP claimed
EP-0354571-A1 Oximethers, method for their preparation and fungicides containing them BASF Aktiengesellschaft (DE) 1990-02-14 EP claimed
US-4777185-A Phenyl phenoxyphenyl propenyl cyclopropane pesticides NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1988-10-11 US claimed
EP-0179788-A1 PESTICIDES. NAT RES DEV (GB) 1986-05-07 EP claimed
WO-1985004651-A1 IMPROVEMENTS RELATING TO PESTICIDES NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1985-10-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A HTR3A 1665/4885DRD2 3103/4885SLC2A1 500/4885
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS TTBK1, MAP3K1, TNNI3K HTR3A 3957/4885DRD2 4873/4885SLC2A1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.